HVTN Principal Investigator
Vaccine and Infectious Disease Division
HVTN Executive Director
James Kublin currently serves as the HVTN Executive Director, coordinating global operations across the prevention and therapeutic HIV Clinical Trials Network as well as alliance management for the Collaboration for HIV Vaccine Discovery funded by the Bill & Melinda Gates Foundation. His research interests recently took him to Malawi where he established several study sites evaluating anti-malarials and the interactions between HIV and malaria. Dr. Kublin’s current work includes developing and testing preventive HIV and tuberculosis vaccines via the HVTN, along with a Grand Challenges grant to apply high-throughput system analyses to malaria vaccine development.
Principal Investigator of the HVTN Statistical Data Management Center
Peter Gilbert currently serves as the Principal Investigator of the Statistical Data Management Center for the HVTN. Dr. Gilbert led the statistical design and analysis of an immune correlates study of the RV144 “Thai Trial” (published in 2012), which established a process for correlates discovery that may be useful for other vaccine trial settings. In addition, he led the statistical design of a sequential phase 2b trial for evaluating vaccine efficacy and immune correlates for multiple HIV vaccine regimens (published in 2011), which is planned for implementation in future vaccine trial settings.
Principal Investigator of the HVTN Laboratory Program
Julie McElrath is the Principal Investigator of the HIV Vaccine Trials Network Laboratory Program and the Seattle HIV Vaccine Trials Unit. Dr. McElrath's laboratory seeks to identify significant immune responses associated with HIV-1 prevention and control, with studies encompassing a broad range of translational research investigations in persons who experience unusual control of HIV-1. The lab focuses on understanding the role HIV-1-specfic memory T cells play in protection against mucosal HIV-1 transmission and how to exploit this immune system response for vaccine development.
Director of Clinical Development
Shelly Karuna serves as the Director of Clinical Development for the HVTN and is responsible for coordinating HVTN clinical trial development, contributing to management of the HVTN protocol portfolio and facilitating intra- and extra-Network collaboration. As a Clinical Trials Physician/Protocol Team leader, she also coordinates medical monitoring oversight for HIV vaccine clinical trials, especially concerning vaccine safety and immunogenicity.
Director, Cape Town HVTN Immunology Laboratory
Erica Andersen-Nissen is directing cellular studies of specimens from HVTN trials in Southern Africa at the Cape Town HVTN Immunology Laboratory (CHIL). She has worked to incorporate innate immune response assays into the HVTN and has contributed extensively to clinical trial protocol development in the HVTN. Her future work will examine immune responses to HIV vaccines in Southern African populations.
Associate Director of Scientific Support
Ann Duerr is the HVTN Associate Director of Scientific Support. She has published extensively on biological and epidemiological determinants of HIV transmission and interaction with other sexually transmitted diseases.
Associate Director of Laboratory Operations
John Hural is the Associate Director of Laboratory Operations. This group is responsible for overall coordination of a variety of trial related laboratory activities, including monitoring the oversight of immunologic and virologic endpoints, processing specimens and overseeing safe practices. This group is also responsible for general study support, specimen management, program quality assurance, and fiscal management of the Laboratory Program.
Associate Director of HVTN Laboratory Science
Nicole Frahm is the Associate Director of Laboratory Science of the HVTN. Her current studies focus on elucidating cellular mechanisms for control of HIV replication and assessing cellular immune responses in HIV vaccine recipients.